Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Among authors: iriagac y. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: iriagac y. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31. J Cancer Res Clin Oncol. 2022. PMID: 34331582
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: iriagac y. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23. Future Oncol. 2022. PMID: 35734870
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study.
Almuradova E, Basoglu T, Nayir E, Bayram E, Paydas S, Gokmen I, Karakaya S, Oksuzoglu B, Erdem D, Sakin A, Atcı M, Belen Gulbagcı B, Hacibekiroglu I, Onder AH, Karaarslan S, Karakurt Eryılmaz M, Korkmaz M, Yazıcı O, Sutcuoglu O, Akagunduz B, Arak H, Sakalar T, Aydin D, Iriagac Y, Alan O, Midik M, Cetin D, Kip AD, Turhal S, Kacan T, Koseci T. Almuradova E, et al. Among authors: iriagac y. Neoplasma. 2023 Feb;70(1):158-165. doi: 10.4149/neo_2022_221004N984. Epub 2023 Jan 9. Neoplasma. 2023. PMID: 36620878
Major and minor salivary gland cancers: A multicenter retrospective study.
Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Selçukbiricik F, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Hacioglu MB, et al. Among authors: iriagac y. Head Neck. 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21. Head Neck. 2023. PMID: 37084179
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.
Avcı O, İriağaç Y, Çavdar E, Karaboyun K, Araz M, Şakalar T, Değerli E, Özdemir Ö, İnal A, Ocak B, Ürün M, Sakin A, Yıldız Tacar S, Koçak MZ, Demir H, Özer Ö, Tanrıkulu Şimşek E, Ersoy M, Karakaş Y, Arıkan R, Eşbah O, Ön S, Şenocak Taşçı E, Molinas Mandel N, Türker S, Kaçan T, Yıldırım HÇ, Alan Ö, Akbaş S, İpek Deniz G, Aydın İsak Ö, Taşkaynatan H, Şeber ES. Avcı O, et al. Among authors: iriagac y. J Geriatr Oncol. 2023 Nov;14(8):101604. doi: 10.1016/j.jgo.2023.101604. Epub 2023 Sep 6. J Geriatr Oncol. 2023. PMID: 37683369
24 results